Aromatase inhibitors are superior to tamoxifen in postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties.

• 芳香酶抑制剂在绝经后患者中优于他莫昔芬，且临床前数据表明唑来膦酸具有抗肿瘤特性。